Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Holbrook E K Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq et al. · Blood · 2014

To the editor: Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) with promising activity in CD20+ B-cell malignancies including recent US Food and Drug Administration approval in mantle cell lymphoma.[1][1] Given the homology between BTK and interleukin-2 inducible tyrosine

Cited by 217 works. doi:10.1182/blood-2014-01-547869

Authors

References